Enliven Therapeutics Inc. (ELVN NASDAQ) stock market data APIs
$41.3813
0.02(0%)
as of October 9, 2026
Try our APIs with
free plan!
Enliven Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Prev. Close
41.3813
Open
41.4013
High
42.0607
Low
39.9889
52 wk Range
14.785-62.32
Market Cap
3 003 M
Shares Outstanding
73 271 K
EPS
-0.49
Beta
0.337
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Enliven Therapeutics Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Enliven Therapeutics Inc. data using free add-ons & libraries
Get Enliven Therapeutics Inc. Fundamental Data
Enliven Therapeutics Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -124 284 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Enliven Therapeutics Inc. Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -0.38
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enliven Therapeutics Inc. News
New
Enliven, FDA agree on phase 3 trial design for relcobatinib for chronic myeloid leukemia
[Chronic myeloid leukemia cells or CML, analyze by microscope. Blood cancer cells image] Md Ariful Islam/iStock via Getty Images * Enliven Therapeutics (ELVN [https://seekingalpha.com/symbol/ELVN])...
10 mid-cap healthcare stocks with the strongest momentum grades
Mid-cap U.S. healthcare stocks have exhibited strong momentum traits year to date, with several names earning A-range momentum grades that indicate stronger price performance trends relative to sector...
Miners And More Lead Slew Of Stocks To Watch — With This Line In Focus
Miners like Southern Copper and Newmont lead this screen of stocks to watch in or near buy range alongside UBS, Garmin and more. Continue Reading
5 Biotech Stocks That Delivered Big Gains - Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLX
(RTTNews) - As Warren Buffett once said, "If you find three wonderful businesses in your life, you'll get very rich." His message underscores the importance of identifying a handful of exceptional com...
Get Enliven Therapeutics Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.